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Abstract
Experimental and clinical experience demonstrates that the resolution of a pathogenic challenge
depends not only on the presence or absence of an immune reaction, but also on the initiation of
the proper type of immune reaction. The initiation of a non-protective type of immune reaction
will not only result in a lack of protection, but may also exacerbate the underlying condition. For
example, in cancer, constituents of the immune system have been shown to augment tumor
proliferation, angiogenesis, and metastases. This review discusses the duality of the role of the
immune system in cancer, from the theories of immunosurveillance and immunostimulation to
current studies, which illustrate that the immune system has both a protective role and a tumor-
promoting role in neoplasia. The potential of using chemotherapy to inhibit a tumor-promoting
immune reaction is also discussed.
If only it were all so simple. If only there were evil people some-
where insidiously committing evil deeds, and it were necessary
only to separate them from the rest of us and destroy them. But
the line dividing good and evil cuts through the heart of every
human being, and who is willing to destroy his own heart?
Alexander Solzhenitsyn, The Gulag Archipelago
The notion that the immune system may be manipulated
into recognizing and eradicating neoplasia is not new.
Heroic efforts to develop a cancer vaccine can be traced as
far back as 1777 when the surgeon to the Duke of Kent
injected himself with malignant tissue as a prophylaxis
against development of cancer. In 1808, another attempt
was made to develop a cancer vaccine by the doctor to
Louis XVII who inoculated himself with breast cancer in
hope of reversing a soft-tissue sarcoma, although no ther-
apeutic effect was observed. However, it was not until
1891 that the first report of successful immunotherapy
was published by William Coley, a clinician at the Memo-
rial Sloan Kettering Cancer Institute in New York. Using
heat-killed endotoxin-containing bacteria (streptococci
and Serratia marcescens), Coley was able to achieve a cure
rate of 10% in soft-tissue sarcoma [1,2]. Nevertheless,
despite the numerous attempts over the past centuries to
use the immune system in the eradication of cancer, the
success rate of cellular immunotherapy remains abys-
mally low.
In light of the successes in the development of vaccines
targeting pathogenic agents, this review suggests that les-
sons learned from the immunology of infectious disease
may be applicable to the treatment of neoplasia. The
immunology of infectious disease teaches that the clear-
ance of a pathogenic challenge requires the initiation of
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tity. Clinical experience demonstrates the perils of an
inappropriate immune reaction. Pathogens may be of an
intracellular (viral, some bacterial strains) or extracellular
(bacterial, parasitic) nature; accordingly, the specific
immune response is bifurcated into a cell-mediated
branch, which offers protection against intracellular path-
ogens, and an antibody-mediated branch, which offers
protection against extracellular pathogens. Following a
challenge with Mycobacterium leprae, the leprosy inducing
bacterium, a cell-mediated immune response will result in
protection whereas an antibody-mediated immune
response will result in cachexia and disease progression
[3]. The ability of the immune system to act as a double-
edged sword implies that in any given condition the initi-
ation of an immune response may result in either protec-
tion or destruction of healthy tissue. An appreciation of
the duality of the immune reaction is imperative in the
design of immunotherapeutic approaches that attempt to
attain a therapeutic benefit through the manipulation of
the immune system.
Two distinct theories aim to define the role of the immune
system in cancer. The theory of immunosurveillance pos-
tulates that the role of the immune response in cancer is
one of protection – the organism is patrolled for incipient
tumor cells by the effector cells of the immune system. In
contrast, the theory of immunostimulation postulates
that, while in experimental systems highly immunogenic
tumors may be eradicated by the immune response, the
role of the immune response in spontaneous neoplasia is
not one of protection, but rather of tumor promotion.
This review gives a historical overview of these theories
and highlights recent data supporting the validity of both
immunosurveillance and immunostimulation. To explain
the conflicting roles of the immune response in neoplasia
it must be noted that the immune system is not a single
entity, but a complex system of constituents. While these
theories have historically been considered to be mutually
exclusive, it is proposed that these theories describe the
activation of different constituents of the immune system
and hence illustrate that an appropriate immune reaction
will result in protection whereas an inappropriate
immune reaction will result in tumor promotion.
The theory of immunosurveillance
The rise of the theory of immunosurveillance
As early as 1909 Paul Ehrlich postulated that cancer occurs
spontaneously in vivo and that the immune system is able
to both recognize and protect against it [4]. In the late
1950s Lewis Thomas [5] introduced the theory of immu-
nosurveillance, which was subsequently developed by Sir
MacFarlane Burnet [6]. The theory postulates that effector
cells of the immune system actively patrol the body to
identify and eradicate incipient tumor cells. Following the
identification of T cells in the 1970s, these became the
effector cells postulated to mediate immunosurveillance.
The concept of immunosurveillance initially had much
intellectual appeal. First, it could explain clinical observa-
tions of spontaneous remission. Second, the most potent
chemical carcinogens, dimethlybenzanthracene [7], ure-
than [8] and other polycyclic hydrocarbons [9], are also
powerful immunosuppressors, their suppressive effects
being apparent even after a single exposure [7]. Third, spe-
cific immune responses had been observed in the trans-
plantation of chemically induced tumors. Finally, the
theory of immunosurveillance was developed at a time
when the only known function of T cells was to reject for-
eign grafts; thus, there was a clear need to further deter-
mine the biological function of these cells.
Discrepancies in the theory of immunosurveillance
A number of discrepancies were noted in the theory of
immunosurveillance as initially described by Thomas and
Burnet, where T-cells function as the effector cells mediat-
ing immunosurveillance. First, T-cell deficient (athymic
nude) mice did not develop significantly more cancers
than control mice [10] Second, a corollary of the theory of
immunosurveillance is that patients who lack an immune
response would have an increased incidence of neoplasia.
While this has been reported in immunosuppressed
patients who have undergone renal transplant, most of
these tumors (as many as 60%) were reported to be hema-
tological malignancies or neoplasms with viral etiology. It
would be reasonable to expect the immune system to pro-
tect against viral carcinogenesis, as the protective role of
the immune system against viral pathogens is well estab-
lished. One interpretation of these results is that the pre-
disposition toward hematological malignancy is due to
the viral etiology of certain lymphomas (which are
thought to be caused by the Epstein-Barr virus). The only
non-lymphoid tumors that increase significantly upon
immunosuppression are non-melanoma skin cancers, cer-
vical carcinoma and Kaposi's sarcoma (the latter two hav-
ing a viral etiology, specifically the human papilloma
virus and human herpes virus 8, respectively). In these
early studies, the incidence of most tumor types was not
increased by immunosuppression [11]. In fact, the inci-
dence of mammary carcinomas actually decreases in
immunosuppressed individuals [12]. A third discrepancy
is that diseases such as leprosy, sarcoidosis and uremia,
which are characterized by immunosuppression, are not
accompanied by an increased incidence of tumors
[13,14]. Finally, the theory of immunosurveillance pre-
dicts that sites that are excluded from the immune system
– that is, sites of immunological privilege such as the ante-
rior chamber of the eye and the brain – should have an
increased incidence of cancer. However, this is not the
case.Page 2 of 13
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may not be immunogenic. A correlation between the dose
of carcinogen administrated and the immunogenicity of
the subsequent tumor has been reported in mouse models
[15-17]. Since human tumors most likely occur as a result
of low exposure to carcinogens, incipient tumors would
be expected to be poorly immunogenic. In addition, since
incipient tumors would contain few cells, the question
arises of whether the antigenic load would be sufficient to
induce a response [18]. This phenomenon may be
observed in the immunology of infectious diseases where
naïve C57Bl/6 mice challenged with Taenia taeniaeformis
will reject a large inoculum of the cestode larva yet will
succumb to infection by minute inoculations [19].
Finally, it is only in recently years that the tumor specific-
and not tumor associated antigens have been identified
[20].
The revivification of immunosurveillance
Over the past two decades, data have emerged suggesting
that constituents of the immune system such as natural
killer (NK) cells and cytokine networks may be able to
guard against cancer. Furthermore, recent studies of the
incidence of neoplasia in immunosuppressed patients
after organ transplantation, in contrast to earlier studies,
reported that these patients are more susceptible to a wide
range of cancers, including epithelial cancers [21,22].
Natural killer cells
Several studies suggest that NK cells are able to protect
against tumors. Beige, natural-killer-cell defective, mice
have an increased incidence of spontaneous tumors [23]
and cancer metastases [24-28]. This is consistent with the
pattern seen in patients with Chediak Higashi syndrome,
an autosomal recessive disorder characterised by abnor-
mal NK cytotoxic function. These patients also have a 200-
fold increased risk of developing malignancy [29]. Fur-
thermore, several studies show that cancer cells secrete
soluble factors that suppress NK cells in vitro [30-32] and
that patients with a variety of tumor types have suppressed
NK cell activity [33-38]. NK cell activity is also a positive
prognostic indicator in several tumor types [39-43]. These
data suggest that NK cells are involved, directly or indi-
rectly, in the surveillance of incipient tumors and
micrometastases. This theory is further substantiated by
data showing that oncogene-transfected fibroblasts can be
selectively lysed by NK cells while sparing untransfected
controls [44].
The precise mechanism though which NK cells mediated
immunosurveillance is not yet understood. It is likely that
the role of NK cells, in addition to their direct cytotoxic
effects, is to activate other cells of the immune system
through providing cytokine support [45]. Mature NK cells
do not produce T-helper 2 (Th2) cytokines, but rather the
T-helper1 (Th1) cytokines tumor necrosis factor (TNF)-α,
interferon (IFN)-γ and GM-CSF [46]. In fact, secretion of
IFN-γ by NK cells can influence the development of a Th1
type immune response both against pathogenic agents
and against MCA-induced tumors [47].
Cytokine networks
The initiation of an immune response requires cytokine
support provided by T-helper cells. The nuance of
cytokines produced by these cells determines the type of
immune response initiated. The initiation of a cell-medi-
ated immune response requires the support of Th1
cytokines, while the initiation of an antibody-mediated
immune response requires the support of Th2 cytokines.
T-helper cells that have differentiated into Th1 cells
secrete IFN-γ and to a lesser extent interleukin (IL)-2 and
IL-12, whereas Th2 cells secrete IL-10, IL-4 and to a lesser
extent IL-5.
The cell-mediated immune response is generally regarded
as possessing tumor-inhibitory activities both clinically
and in animal models [48-51]. Accordingly, a number of
studies suggest that the expression of Th1 cytokines is
associated with a favorable clinical outcome, while the
expression of Th2 cytokines is associated with an unfavo-
rable clinical outcome. In renal-cell carcinoma, the pres-
ence of an IL-4 receptor polymorphism that resulted in an
increase in IL-4 signaling and an increased likelihood of a
Th2 response was an independent indicator of adverse
prognosis [52]. In other studies of patients with renal can-
cer, an elevated level of IL-10 was an adverse prognostic
indicator [53], while the serum levels of IFN-γ were nega-
tively correlated with tumor mass [54]. In malignant
melanoma, patients that had an early relapse had lower
serum levels of IL-2 and IL-12. Furthermore, decreases in
the serum concentrations of IL-2 and IL-12 and increases
in IL-10 were observed at least one month before relapse
[55]. In B-cell diffuse large cell lymphoma, patients who
achieved complete remission had a higher ratio of Th1 to
Th2 cells [56]. Finally, in a range of advanced solid can-
cers, the serum IL-10 level was an independent prognostic
indicator of overall survival and time to treatment failure
[57]. These data suggest that the Th1-Th2 paradigm is rel-
evant to cancer, although it should be noted that the Th1/
Th2 paradigm is a generalization and that these data show
a correlation, and as such are not evidence of a causal rela-
tionship. Since many tumors secrete IL-10, it is possible,
for example, that the relationship between expression of
IL-10 and tumor prognosis reflects the poor prognosis of
patients with a larger tumor burden. This is plausible
given that the role of IL-10 in tumor immunology is com-
plex (reviewed in [58]). IL-10 appears to be a pleotropic
cytokine whose reported effect is a function of the
nuances of the experimental system. While several reports
suggest that IL-10 is immunosuppressive, several groupsPage 3 of 13
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cells [59]. In addition, IL-10 transfected into murine carci-
noma models decreases tumorigenicity and sensitizes
tumor cells to immune mediated lysis by either NK cells
or NK cells and cytotoxic T-cells [60-62]. Clinical data fur-
ther corroborates a protective role for IL-10 in tumor
immunology by showing that metastatic melanoma
patients who responded to an immunotherapeutic regi-
men had tumors with significantly higher expression of
IL-10 mRNA as compared to patients that did not respond
[63,64].
Furthermore, tumors have a number of specific and non-
specific ways of evading a Th1 response. Tumors secrete a
number of agents, including transforming growth factor
(TGF)-β, IL-10 and prostaglandin E-2, which have been
shown to promote a Th2 immune response while sup-
pressing the Th1 immune response. Indeed, it has been
shown that the cytokine networks of some cancer patients
are skewed toward Th2 [55,65,66]. That is, these patients
exhibit enhanced expression of Th2 cytokines or
decreased expression of Th1 cytokines systemically or in
the local tumor microenvironment. The observation that
tumors have developed numerous methods of evading
the Th-1 response is consistent with the notion of immu-
nosurveillance. Nowell's clonal-evolution hypothesis pos-
tulates that cancer is a Darwinian process: mutations that
provide a growth or survival advantage will be selected for
in the population [67]. The fact that malignancies have
many ways of evading the Th-1 response suggests that the
ability to evade this response confers a survival advantage
on malignant cells, which further suggests that the Th-1
response poses a threat to the neoplasm.
Interferon-γ
The Th-1 cytokine IFN-γ has both direct and indirect anti-
tumor properties. A series of experiments have demon-
strated the importance of IFN-γ in eradicating incipient
tumors by showing an increase in the efficacy of carcino-
genesis in the absence of IFN-γ. These experiments were
conducted either with neutralizing antibodies to IFN-γ or
in animal models deficient in IFN-γ, the IFN-γ receptor or
downstream signaling mechanisms of IFN γ, specifically,
the signal transducer and activator of transcription-1 pro-
tein. In all of these models, an increase in the incidence of
MCA-induced tumors and a decrease in the latency period
of the tumors were observed [68-71]. Furthermore, an
increase in the number of spontaneous lymphomas and
lung tumors was observed in IFN-γ deficient mice com-
pared with genetically matched wild-type controls [72].
IFN-γ may inhibit tumor growth by affecting prolifera-
tion, apoptosis and angiogenesis. IFN-γ has been shown
to have a direct anti-proliferative effect on certain tumor
models [73-75]. It is thought that this effect is mediated
through p21 (WAF1/CIP1) and p27 (kip1) as IFN-γ acti-
vates these tumor suppressors [76,77]. Furthermore, IFN-
γ has been reported to modulate apoptosis in certain
models [78,79] by inducing expression of caspase 1 and
Fas/FasL [80,81]. With respect to angiogenesis, IFN-γ
induces expression of three angiostatic non-ELR (non-
Glu-Leu-Arg) chemokines: interferon-gamma-inducible
protein 10 (IP-10), monokine induced by gamma inter-
feron and interferon-inducible T-cell alpha chemoattract-
ant [82-84]. The effects of these chemokines on
angiogenesis will be discussed.
IFN-γ may also have indirect antitumor effects by stimu-
lating an effective antitumor immune response. In addi-
tion to influencing the Th1-Th2 cytokine balance, IFN-γ
can activate cytotoxic macrophages, NK cells and NK T
cells [85].
The theory of immunostimulation
The proof of the principle that an inappropriate type of
immune response will enhance tumor growth was dem-
onstrated as early as 1907 by Flexner and Jobling, who
showed that injection of dead autologous tumor cells
enhanced the growth of pre-existing tumors [86]. In gen-
eral, Th2-driven antibody responses to tumors are non-
protective and may contribute to tumor progression by
inhibiting the Th1 cell-mediated immune response [87].
However, the notion that the antibody-mediated immune
response may be detrimental in cancer was suggested long
before Mossman and Coffman demonstrated the Th1-Th2
paradigm in 1986 [88]. In the 1950s Kaliss popularized
the term "immunological enhancement" to describe the
enhancement of tumor growth by non-cytotoxic antibod-
ies [89]. It was theorized that these antibodies bind to
tumor cells, masking their epitopes and thus preventing a
cell-mediated immune response, although this has never
been demonstrated experimentally.
In 1972, Richmond Prehn formulated the theory of
immunostimulation of tumor growth [90]. This theory
states that, in contrast to the strong immune response gen-
erated by transplantable tumors, a quantitatively mild
immune response, such as that generated by spontaneous
tumors, is stimulatory to the growth of neoplasia. Several
experimental observations support the hypothesis that
such a weak immune response to cancer may stimulate
tumor growth. The co-injection of lymphocytes (spleen
cells) from syngeneic mice that had been growing tumors
for 10–20 days with tumor cells from MCA-induced sarco-
mas into thymectomized irradiated syngeneic mice at a
range of doses accelerated tumor growth when the ratio of
lymphocytes to tumor cells was low [90]. However, when
the ratio of lymphocytes to tumor cells was high, lym-
phocytes from specifically immunized mice inhibited
growth compared with naïve lymphocytes that continuedPage 4 of 13
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biphasic dose response whereas a "weak" immune
response results in stimulation of tumor growth while a
strong immune response results in protection.
This premise is also demonstrated in another study where
MCA induction of tumors occurred more rapidly in irradi-
ated thymectomized mice that had received increasing
doses of lymphocytes (spleen cells) to partially restore
their immune system than in mice that had either fully
restored or unrestored immune systems [91]. Comparable
results have been observed in mice that have had their
immune systems compromised to various degrees by irra-
diation [92] and in T-cell deficient nude mice that have
had their immune systems partially restored by the injec-
tion of various quantities of thymic or spleen cells [93].
These studies support the notion that a weak antitumor
immune response will not confer protection and may
exacerbate tumor growth.
Furthermore, in transplantation immunology, an
immune response against a graft generally promotes graft
rejection. However, rabbits that received skin grafts of
similar but not identical major histocompatibility com-
plex launched an immune response that resulted not in
rejection but in enhanced growth of the tissue, resulting in
hyperplasia [94]. This is consistent with the notion that a
quantitatively "weak" immune response against a tumor
may enhance tumor growth.
Collectively, these data support the essence of the theory
of immunostimulation: specifically, that spontaneous
tumors may not stimulate an appropriate immune
response but rather stimulate non-protective immune
responses that quantitatively are not adequate for tumor
eradication. These resulting "weak" immune responses
are not merely non-protective but actually facilitate tumor
growth. Specifically, a "weak" immune response is a state
in which immunological recognition of the tumor occurs
but resolution is not achieved. As this theory was devel-
oped in an era when our understanding of the composi-
tion of the immune system was limited, the exact
mechanism by which a "weak" immune response stimu-
lates tumor growth has yet to be defined in the terminol-
ogy of contemporary immunology. Recent data, however,
suggest numerous mechanisms by which the immune sys-
tem can facilitate tumor growth and progression.
Inappropriate immune reactions exacerbate cancer
Based on the observation that a tumor is in a state of
chronic inflammation, Dvorak compared cancer to a
wound that never heals [95]. Numerous tumor types con-
stitutively produce cytokines and chemokines; this results
in the migration of leukocytes into tumors. Unfortu-
nately, these immune infiltrates often do not offer protec-
tion but actually facilitate tumor growth. Tumor-
infiltrating leukocytes can facilitate tumor progression by
secreting growth factors, reactive oxygen and nitrogen spe-
cies, proteases, prostaglandins and angiogenic growth fac-
tors. Reactive oxygen and nitrogen species may directly
promote tumor progression by inducing DNA damage,
and hence the acquisition of additional mutations. In
addition, these cells may skew the cytokine milieu to favor
the generation of a non-protective Th2 immune response.
Mast cells and macrophages are examples of inflamma-
tory cells that are often recruited to tumor sites through
chemotactic gradients. The mechanisms by which mast
cells, macrophages and chemokines themselves facilitate
tumor growth and progression are discussed below.
Mast cells
Mast cells are leukocytes that contain inflammatory
agents, such as proteases, histamine and heparin, and
mediate hypersensitivity reactions. The possibility that
mast cells are involved in cancer has been considered
since the late 1800s. In 1877, Paul Ehrlich described a
mast cell for the first time in his doctoral thesis, after iden-
tifying it using histological staining. In subsequent inves-
tigations, he and others observed that mast cells localize
around tumor tissues [96]. Interestingly, mast cells were
more likely to be localized in the periphery than in the
centre of tumor sections. Many types of human tumors
contain mast-cell infiltrates [97-100]. The accumulation
of mast cells in neoplastic tissue results from the secretion
of growth factors such as vascular endothelial growth fac-
tor (VEGF) [101], epidermal growth factor [102], basic
fibroblast growth factor (bFGF) [103,104], platelet
derived growth factor [101] and stem cell factor (SCF)
[105] by the tumor. These cytokines act as chemotactic
agents to induce the migration of mast cells.
A number of studies show a correlation between mast-cell
infiltration and tumor progression. For example, co-injec-
tion of mast cells with an inoculum of rat sarcoma tumors
results in enhanced tumor growth, while pharmacologi-
cally decreasing the quantity of mast cells slows tumor
growth [106]. Furthermore, genetic evidence supports the
role of mast cells in tumor growth and progression. SCF is
important for mast-cell development, proliferation,
migration and degranulation. W/Wv mice (which express
a mutation in the SCF receptor) do not develop functional
mast cells. In W/Wv mice, tumors do not metastasize as
readily and they vascularize at a slower rate than in wild-
type mice. Tumor metastasis and vascularization return to
wild-type levels following restoration of mast cells [107].
Furthermore, administering antisense targeting SCF in a
rat mammary-tumor model results in a decrease in mast-
cell degranulation, microvascular density and tumor
growth [108]. These studies suggest that the presence of
mast cells in tumors is not indicative of a protectivePage 5 of 13
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progression.
The mechanisms by which mast cells facilitate tumor pro-
gression appear to involve the factors contained within
mast-cell granules. Experimental evidence suggests that
degranulation is critical in the ability of mast cells to
enhance tumor growth. Inhibition of mast-cell degranula-
tion using disodium cromoglycate impedes tumor growth
[109]. One of the functions of degranulation in tumor
growth may be to facilitate angiogenesis. Addition of mast
cells or isolated mast-cell granules induces vascularization
in the chorioallantoic membrane model, while no effect
of adding previously degranulated mast cells was
observed [110]. This effect appears to be partially medi-
ated through bFGF and VEGF, as addition of anti-bFGF
and anti-VEGF antibodies significantly decreased the
degree of vascularization. Indeed, mast cells secrete a
number of growth factors that regulate angiogenesis and
endothelial-cell survival, including TNF-α [111], IL-8
[111], bFGF [112] and VEGF [113,114]. Moreover, mast-
cell granules contain the proteolytic enzyme tryptase,
while some mast-cell subsets also contain chymase. These
enzymes have both direct and indirect effects on the integ-
rity of the extracellular matrix (ECM). Directly, these
enzymes induce degradation of ECM components [115].
Indirectly, they can induce degradation of the ECM by
activating latent forms of matrix metalloproteinases
[116]. Furthermore, it has been reported that these protei-
nases may induce proliferation of vascular endothelial
cells [117].
As is often the case in networks, activation of one compo-
nent induces the activation or suppression of interacting
components. Activated mast cells secrete a number of
cytokines that induce the chemotactic migration of mac-
rophages into the tumor, including IL-1, IL-6, TNF-α, IL-
8, monocyte chemotactic protein-1, macrophage inflam-
matory protein-1α and macrophage inflammatory pro-
tein-1β [118,119]. The effect of macrophages on tumor
growth and progression is discussed in the following sec-
tion. In addition, activation of mast cells induces the syn-
thesis of the cylooxygenase enzyme, which is involved in
the metabolism of arachidonic acid [120-122] and pros-
taglandins. Pharmacological inhibition of cylooxygenase
significantly impedes metastasis in several animal models
[123-125].
Macrophages
Macrophage infiltration of tumor sites has been observed
in a range of tumor types. Monocytes are recruited to the
tumor by constitutive tumor-cell expression of chemoat-
tractant cytokines. In fact, the level of expression of mono-
cyte chemotactic protein-1, macrophage colony
stimulating factor (M-CSF) and VEGF by tumor cells cor-
relates well with the extent of macrophage infiltration
[126,127]. Within the tumor microenvironment, mono-
cytes differentiate into macrophages. The role of the mac-
rophage in the tumor microenvironment appears to be
specific to the tumor type. In breast [128], cervical [129]
and bladder [130] cancers macrophage infiltration is an
adverse prognostic indicator. However, in prostate
[131,132], lung [133,134] and brain [135,136] cancers
the prognostic significance of tumor associated macro-
phages, TAMs, depends on the method of assessing mac-
rophage infiltration, the endpoints of the study and the
specifics of the patient cohort. This discrepancy highlights
the chameleon-like nature of the macrophage. Depending
on their microenvironment, macrophages may either
exhibit antitumor cytotoxic activity or facilitate tumor
growth and progression while reinforcing a Th2 biased
immune response [137].
Following exposure to IFN-γ or bacterial lipopolysaccha-
ride, macrophages can exhibit direct or indirect tumor
cytotoxicity. Macrophages may participate in antibody-
dependent cellular cytotoxicity responses if an IgG2a anti-
body binds to a tumor surface antigen. In such a scenario,
the macrophage would bind to the Fc portion of the anti-
body, releasing cytotoxic mediators such as proteinases
and TNF-α. Macrophages may also mediate cytotoxicity
independently of antibodies through the secretion of reac-
tive oxygen and nitrogen species, proteinases and TNF-α.
Furthermore, macrophages of this "cytotoxic" phenotype
affect the cytokine profile of the microenvironment
because they secrete IL-12. IL-12 favors the differentiation
of naïve T-helper cells to Th1 cells, which will subse-
quently secrete IFN-γ and TNF-β. The role of these
cytokines in the promotion of a cell-mediated immune
response has already been discussed. Finally, cytotoxic
macrophages produce matrix metalloproteinase-12 [138].
Matrix metalloproteinase-12 has been shown to convert
plasminogen to angiostatin [139]. Angiostatin is impor-
tant in the inhibition of angiogenesis [140].
In contrast to macrophages that are activated by classical
mechanisms and are capable of cytotoxic activity, TAMs,
for the most part, do not exhibit cytotoxic activity, are Th1
immunosuppressive and, in fact, facilitate tumor growth,
vascularization and metastasis. Tumors secrete a number
of cytokines including IL-4, IL-10, TGF-β, prostaglandin E-
2 and VEGF. These factors modulate the macrophage phe-
notype, changing them from cytotoxic macrophages to
suppressive macrophages [141-143]. Furthermore, TAMs
appear to have functional defects; for example, in contrast
to other macrophages, TAMs are poor antigen-presenting
cells [141] and have reduced cytotoxicity owing to
impaired production of TNF-α [144] and nitric oxide
[145]. However, these impairments in the function ofPage 6 of 13
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vated rather than defective.
A number of studies suggest that TAMs facilitate tumor
growth, vascularization and metastases. As previously
stated, numerous studies have shown the presence of
TAMs to be an adverse prognostic indicator. In addition,
genetic evidence suggests that macrophages are important
in vascularization and metastasis of experimental tumors.
To assess the role of macrophages in carcinogenesis, the
M-CSF deficient osteoporotic (op/op) mouse was crossed
with the polyoma virus middle T transgenic mouse, which
develops spontaneous mammary tumors. While no differ-
ences were observed in the early stages of tumor growth,
the resulting offspring of these tumor-bearing mice had a
reduced rate of progression to invasive carcinoma and
contained fewer pulmonary metastases than control mice
[146]. Furthermore, induced M-CSF expression in the
mammary tissue of these mice resulted in restored meta-
static spread of experimental tumors. In addition, trans-
plantation of the Lewis lung carcinoma in the op/op
mouse resulted in a decrease in its growth and vasculari-
zation compared with wild-type littermates [147]. This
attenuation could be reversed by administration of M-
CSF. These data suggest that macrophage infiltration is
important in angiogenesis and tumor progression.
Interestingly, TAMs are not found ubiquitously within
tumor tissue. Data suggest that TAMs localize to poorly
vascularized regions – that is, regions characterized by
hypoxia, low pH and tissue necrosis [127,148-150]. In
response to hypoxia, macrophages express a number of
hypoxia-regulated gene-products, including VEGF,
hypoxia inducible factor 1α and hypoxia inducible factor
2α [149,151,152]. Furthermore, hypoxic conditions
impair the chemotactic migration of macrophages
[150,153]. This suggests that macrophages could be
detained in regions of low oxygen tension. While the pre-
cise nature of the relationship between macrophages and
hypoxia requires further investigation (macrophages are
phagocytic cells, so their physiological role may well be to
engulf necrotic tissues), it is possible that macrophage
recruitment to these sites facilitates angiogenesis.
One mechanism by which TAMs may augment angiogen-
esis is through the production of a plethora of cytokines
and proteinases. As mentioned above, hypoxia induces
production of VEGF. The angiogenic properties of VEGF
have been extensively discussed by others [154]. In addi-
tion to VEGF, the repertoire of cytokines produced by
TAMs includes granulocyte macrophage colony-stimulat-
ing factor, TGF-α, TGF-β, IL-1, IL-6, IL-8 and prostaglan-
din E-2. These cytokines are involved in the regulation of
angiogenesis. Furthermore, TAMs secrete urokinase-type
plasminogen activator and matrix metalloproteinase-9
[155,156]. These proteinases are involved in the induc-
tion of angiogenesis and metastasis through degradation
of the ECM.
Finally, TAMs have numerous indirect immunological
effects. TAMs produce copious amounts of IL-10 but low
amounts of IL-12 [157]. This shift in the cytokine profile
reinforces the Th2 imbalance that is often present in can-
cer models. More significantly, IL-10 prevents T-cell acti-
vation by inducing a state of anergy (a state of T-cell non-
responsiveness associated with tolerance induction). IL-
10 can induce anergy both in T cells that have been acti-
vated in its presence and in T-cells activated by antigen-
presenting cells that were previously exposed to IL-10
[158]. These data suggest that TAMs may also facilitate
tumor growth by inducing tolerance to the tumor and
hence suppressing the antitumor immune response.
Chemokines
Chemokines are a subclass of cytokines that direct the
migration of leukocytes to sites of inflammation. It has
recently been observed that tumors express chemokine
receptors [159-161]. Thus, it should not come as a sur-
prise that, aside from their role in mediating the recruit-
ment of tumor-infiltrating leukocytes to tumor sites,
chemokines may also affect neoplastic proliferation, neo-
vascularization and metastasis. Specific chemokines, such
as growth-related oncogene (GRO)-α, GRO-β, GRO-γ and
IL-8, directly induce the proliferation of melanoma cells
[162], while ligands of the chemokine receptor CXCR-2,
such as IL-8, induce proliferation of lung [163,164], ovar-
ian [165], pancreatic [166] and head and neck [167]
tumors. Chemokines may both augment and inhibit ang-
iogenesis. In general, chemokines with an ELR motif pro-
mote angiogenesis and facilitate the chemotactic
migration of endothelial cells [168]. Nevertheless, IFN-γ
induces the expression of three non-ELR chemokines that
have been reported to have angiostatic properties. For
example, expression of IP-10 is negatively correlated with
human lung-cancer tumor growth [169], while adminis-
tering recombinant IP-10 slows tumor growth [170]. Fur-
thermore, administration of IL-12 inhibits bFGF-
mediated in vivo neovascularization of matrigel [171]. The
angiostatic effects of IL-12 appear to be mediated through
the induction of IP-10 and of monokine induced by
gamma interferon, as neutralizing antibodies to these
chemokines negated the angiostatic effects of IL-12
[172,173]. Finally, in some systems IL-8 activates the tran-
scription of matrix metalloproteinase and is associated
with an increased degree of invasion and metastasis. Fur-
thermore, chemokines may be involved in the attraction
of circulating cancer cells to sites of metastasis [174-177].Page 7 of 13
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Based on our knowledge of tumor immune evasion and
immune contribution to growth of tumors, several thera-
peutic implications arise including: a) Use of adjuvant
therapies to decrease tumor immune suppression while
vaccination, b) Extracorporeal elimination of immune
suppressive molecules; and c) Gene silencing of tumors to
generate immunity.
The armamentarium of clinically useful drugs for inhibi-
tion of tumor immunity is rapidly growing. The challenge
is to identify drugs that intrinsically possess antitumor
activity, while at the same time can reverse immune stim-
ulation. One promising candidate that fits these criteria is
the clinically used anti-VEGF antibody bevacizumab
(Avastin). Currently approved by the FDA for treatment of
advanced colon cancer patients, this antibody is believed
to mediate its effects primarily by inhibition of angiogen-
esis [178]. From the tumor immunotherapy perspective,
VEGF plays an important role for tumor suppression of
immune responses. In fact, administration of anti-VEGF
antibody increases efficacy of immunotherapy in mouse
models [179]. Mechanisms by which VEGF inhibits anti-
tumor immunity include suppression of NF-kB activation
in DC resulting in an immature phenotype [180], as well
as suppression of T cell activation [181]. Suppression of
immune inhibitory molecules could also be accom-
plished by immunization. For example, the pregnancy
associated molecule human chorionic gonadotropin
(hCG) is associated with inhibition of Th1 generation in
vitro as well as in vivo [182].
Vaccination with the carboxy-terminal peptide of hCG has
been shown to break tolerance to this self-molecule and
induce a marginal anticancer response [183]. Combining
vaccination against immune suppressive molecules with
vaccination against tumor-specific antigens will likely
improve efficacy.
Another method of reversing tumor associated immune
suppression would involve extracorporeal removal of
inhibitory molecules. Although plasmapheresis tech-
niques have been attempted with mediocre success [184],
a novel and promising method involves ultrapheresis.
Lentz et al described a pilot study of 16 metastatic patients
in which the <100,000 kDa fraction was removed through
membrane ultrapheresis, Six of the 16 patients had reduc-
tion of the sum of mean cross-sectional diameters of
measureable lesions by 50% or more. Additionally, tumor
infiltrating lymphocytes were observed in many of the
lesions after 2 months of treatment [185]. Follow-up stud-
ies demonstrated that the immune suppressive compo-
nent being removed through the ultrapheresis procedure
was soluble TNF-R alpha [186]. Recent developments in
hollow-fiber technologies allow for specific removal of
plasma bourne components such as HIV gp120 and vari-
ous toxins [187]. Applications of these techniques to
immune therapy could yield valuable new approaches
that are currently not studied.
The introduction of RNA interference (RNAi) as a potent
method of gene-specific silencing has opened new territo-
ries for gene therapy. Successful use of RNAi for immune
modulation was first reported by Hill et al [188]. Subse-
quently, it was demonstrated that silencing of the inhibi-
tory cytokine IL-10 led to the generation of dendritic cells
with potent Th1 priming abilities [189]. More recently,
siRNA modified DC were used for induction of antitumor
immunity [190]. The fact that naked siRNA can be directly
endocytosed by target cells [191], or administered using
polyethylenimine-complexe [192], suggests the possibil-
ity of direct intratumoral injection of siRNA targeting
immune suppressive molecules. Additionally, tumor-tar-
geting immunoliposomes could be used for systemic
delivery of siRNA into cancer cells. Suitable targets would
include the wide variety of immune suppressive mole-
cules mentioned above.
Conclusions
The debate on the role of the immune system in cancer
has been one of the most controversial areas of science
with opinions vacillating from optimistic highs to skeptic
nadirs on a cyclical basis. These oscillations in opinion
that are reflective of the relative progress in the immuno-
therapy of cancer, can be explained by the complexity of
the relationship of the immune system and cancer – an
interaction that can result in anti-tumor protection, tumor
promotion, or in no net effect. The apparent schizoid role
of the immune system in cancer may in fact be a variation
on a theme borrowed from the immunology of infectious
disease. That is, the mere generation of an immune
response is not sufficient to attain protection against a
pathogen: it is only an immune response of the proper
type and the proper magnitude that will result in protec-
tion. An immune response against an agent that is not of
the proper type and magnitude will be deleterious to the
host.
A proper type of immune response against cancer will
result in protection. Evidence exists that in set conditions
components of the immune system can recognize and
eradicate incipient cancer cells. It is likely that some sort
of immune surveillance exists in the healthy individual –
though the exact mechanisms have yet to be elucidated.
The genetic evidence discussed herein suggests that NK
cells and IFN-γ are likely to be involved in this protection.
Nevertheless, the clinical presentation of cancer suggests
that neoplasia can evade these putative mechanisms of
immunosurveillance. This further suggests that the ensu-Page 8 of 13
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protective, to control the nascent tumor. However, this
lack of a protective response is not the whole extent of the
role of the immune system in cancer. Several examples
have been presented in which the immune response actu-
ally facilitates tumor growth, neovascularization and pro-
gression. These observations suggest a mechanism that
may explain the theory of immunostimulation, though
undoubtedly, many other mechanisms may exist.
This duality of the immune system in cancer arises in part
because of the decentralized nature of the immune sys-
tem. The non-protective immune reaction that arises
resembles a bureaucratic organization in which a lack of
orchestration between departments results in redundancy
and counter-productivity: the individual entities that con-
stitute the immune system react to the presence of the
tumor yet they are not orchestrated to achieve the end
point of tumor eradication.
Secondly, in advanced tumors, the duality of the immune
system in cancer may also arise from the bilateral nature
of the interaction between the tumor and the immune
mechanisms of the host. Not only can the immune system
affect the tumor, but the tumor may also affect the
immune system. The skewed cytokine milieu of a tumor,
which results in the recruitment of inflammatory cells
through the secretion of chemokines and growth factors
and which further prevents the cytotoxic activation of
these cells, is an example of how the tumor influences the
immune system. This effect of the tumor on the immune
system may be explained by the theory of immunoedit-
ing, which describes the iterative process of selection for
cells that can evade the natural immunosurveillance
mechanisms [193]. This selection process may generate
tumors that not only escape detection by the immune sys-
tem, but that have actually generated mechanisms of
depressing those branches of the immune response that
would offer anti-tumor protection and/or enhancing
those branches that would elicit tumor promotion.
Akin to the successful development of vaccines against
infectious agents, the development of effective immuno-
therapy against cancer will require recognition of the
duality of the immune response in cancer, and the stimu-
lation of the proper type of immune response. The chal-
lenges ahead, especially in late-stage patients who have
undergone immunoediting, will be to overcome the ten-
dencies of the tumor to elicit an inappropriate immune
response, one used by the tumor to promote its own
growth. It may be the case that in subsets of patients the
sort of immunotherapy that is desirable is not that which
stimulates the immune system but that which suppresses
an inappropriate, tumor promoting, immune reaction
[194,195]. Chemotherapy, may in fact be an example of
'immunotherapy'.
Chemotherapy both directly and indirectly affects the
immune system; however, given the multiplicity of the
functions of the immune system in cancer, the net effect
of this treatment modality remains to be defined. While
the direct effect of chemotherapy may be myelosuppres-
sion, this may not be an undesirable consequence given
that cells of the myeloid lineage, such as mast cells and
macrophages, often promote the growth, vascularization
and invasion of tumors. Furthermore, myelosuppression
may actually stimulate a protective, Th1-type, cell medi-
ated immune response because mast cells and macro-
phages secrete factors that promote a Th2 type of immune
response.
"If only it were all so simple." If only the immune system
were all good and it were necessary only to stimulate it to
achieve the eradication of tumors. But the potential for
good and evil is entwined within the heart of the immune
reaction, and who is willing to destroy their own heart?
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